AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

HROW · NASDAQ · Drug Manufacturers - Specialty & Generic

Harrow

Commercializes branded eye medicines and ImprimisRx compounding for US ophthalmology.

$37.77

After-hours close+0.48 (+1.29%)

At close$37.29(−3.24%)

Something off on this page? Send us feedback.

Profile

Harrow Health, Inc.HROWHealth Care

Sells FDA-approved ophthalmic products and runs ImprimisRx, an ophthalmology-focused compounding business. Revenue is centered on branded products, while growth depends on acquired and licensed rights, launch execution, reimbursement, and reliable manufacturing supply.

Commercializes FDA-approved ophthalmic products through the Branded segment, including IHEEZO, VEVYE, TRIESENCE and other specialty eye medicines, and operates ImprimisRx for ophthalmology-focused compounding.

The portfolio is concentrated in the United States, with selected Canadian rights and global rights to Melt assets. Expansion has come through product-rights acquisitions, licenses, and internal work rather than a broad therapeutic footprint.

Execution centers on eyecare commercial channels, supply restoration for acquired products, and preparation for biosimilar and pipeline launches. The business depends on physician adoption, reimbursement, manufacturing quality, supply-chain reliability, and regulatory compliance for labeled promotion and compounded formulations.

Company facts

CEOMark L. Baum

ListedFeb 8, 2013

ExchangeNASDAQ

HeadquartersNashville, TN

CountryUnited States

Employees373

CIK0001360214

ISINUS4158581094

Key statistics

Market cap$1.39B

EPS (ttm)−$0.9938

P/E (ttm)−37.50

ROE-103.9%

P/B91.58

P/S5.04

Dividend yield—

Beta1.49vs XLV 0.45

Year to date −25.3% · Average volume (30d) 553.6K

Analysts

Price target, next 12 months$70.00+87.8%Median of 10 analysts · vs the Aug 28 close

ConsensusBuy10 of 10 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $37.27

High$88.00+136.1%

Median$70.00+87.8%

Low$63.00+69.0%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
May 13, 2026	Cantor Fitzgerald	Reiterate	Overweight	$94	$88
Mar 18, 2026	BTIG	Reiterate	Buy		$63
Mar 4, 2026	H.C. Wainwright	Target		$64	$70
Nov 11, 2025	Cantor Fitzgerald	Target		$76	$94
Sep 29, 2025	Lake Street	Reiterate	Buy	$55	$70

Earnings

EPS

Estimate$0.16

ReportedDue Nov 9, 2026

Revenue

Estimate$98.7M

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	−$0.18	−$0.46	−157.3%	$70.4M	$70.7M	+0.4%	−3.14%
May 11, 2026Q1 FY26	−$0.43	−$0.63	−46.5%	$52.4M	$44.2M	−15.7%	−23.69%
Mar 2, 2026Q4 FY25	$0.40	$0.26	−35.0%	$90.0M	$89.1M	−1.0%	−27.97%
Nov 10, 2025Q3 FY25	$0.22	$0.33	+50.0%	$88.0M	$71.6M	−18.6%	+13.47%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$47.8M	$63.7M	$71.6M	$89.1M	$44.2M	$70.7M
Gross profit	$32.3M	$47.5M	$53.9M	$70.6M	$27.0M	$50.4M
Operating income	−$11.2M	$11.4M	$14.7M	$24.0M	−$22.1M	−$11.0M
Net income	−$17.8M	$5.0M	$1.0M	$6.6M	−$27.6M	−$17.3M
Diluted EPS	−$0.50	$0.13	$0.03	$0.18	−$0.74	−$0.46
Gross margin	67.5%	74.5%	75.3%	79.3%	61.2%	71.3%
Operating margin	-23.5%	17.9%	20.6%	27.0%	-50.0%	-15.6%

Fiscal years (4-quarter sums)FY21 $72.5M · FY22 $88.6M · FY23 $130.2M · FY24 $199.6M · FY25 $272.3M

Revenue by product · Q2 FY26

Product Sales Net$70.6M · 100%

Other Revenues$90.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $83.9M · Total debt $300.7M · Total assets $416.8M · Shareholders' equity $15.2M

Dividends

No dividends on record.

Ownership

Institutions 62.65%23.35M sharesInsiders 11.48%4.28M sharesOther 25.87%9.64M shares

Shares outstanding 37.28M · Float 28.72M · 77.0% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Mark L. Baum · director, officer: CHIEF EXECUTIVE OFFICER	3.00M	8.04%	Form 4	May 15, 2026
BlackRock, Inc.	2.74M	7.35%	13F	Aug 7, 2026
Opaleye Management Inc.	2.40M	6.44%	13F	Aug 14, 2026
Daniel Kaufman	1.88M	5.04%	13G	Mar 11, 2026
Private Capital Management, LLC	1.60M	4.29%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 14, 2026	Amir Shojaei	officer: CHIEF SCIENTIFIC OFFICER	−11,250	$40.00
May 18, 2026	Lauren P. Silvernail	director	+1,000	$31.00
May 18, 2026	Adrienne L. Graves	director	+1,000	$31.07
May 14, 2026	Andrew R. Boll	officer: PRESIDENT AND CFO	+3,500	$29.90
May 14, 2026	Mark L. Baum	director, officer: CHIEF EXECUTIVE OFFICER	+10,000	$30.20